Germany's Medical Cannabis Prescriptions Surge as Prices Drop and Access Simplifies

Germany's medical cannabis market has witnessed a dramatic transformation, with prescriptions skyrocketing by more than 3,300% from March 2024 to December 2025. This surge followed the reclassification of cannabis from a narcotic to a non-narcotic medication, simplifying the prescribing process and expanding telemedical care options. As a result, cannabis has become more normalized as a regulated treatment in the country

Despite the positive developments in access and affordability, concerns over potential misuse have surfaced, prompting discussions about policy changes. According to a new report from Bloomwell Group, these fears are not supported by evidence. The report suggests that tightening access could inadvertently push patients towards unregulated sources, potentially endangering their health

The report, based on data from prescriptions filled by self-paying patients across Germany, highlights the substantial increase in prescription volumes and the corresponding drop in prices. By December 2025, the average price per gram of medical cannabis had fallen from €8.33 to €5.23, while the number of available cannabis products grew significantly. This shift toward affordability and availability is seen as a positive outcome of the reclassification

Bloomwell Group's analysis counters claims of misuse by evaluating prescription data against international medical standards, such as ICD-10 and DSM-5 criteria. The report finds no evidence of increased problematic use or adverse health outcomes. It argues that the streamlined access provided by telemedicine has not led to a rise in new cannabis users but has rather brought existing self-medicating patients into the legal framework

Looking ahead, experts warn that imposing restrictions on telemedicine could reverse these gains. Dr. Julian Wichmann, CEO of Bloomwell GmbH, emphasizes that many patients who previously self-medicated without supervision are now accessing regulated care. Niklas Kouparanis, CEO of Bloomwell Group, advocates for the continuation of digital processes to maintain cost-effective healthcare delivery, warning that dismantling these systems could undermine patient access

The report concludes with a caution against policy reversals, highlighting the risk of driving patients back to unlicensed markets. By maintaining current access levels, Germany can continue to support patient health and safety while avoiding potential pitfalls associated with unregulated cannabis use